Historical News

Taipei, Taiwan, 10 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for March 2026 of NT$4,354 million, represent...

Taipei, Taiwan, 08 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that Zepzelca® (lurbinectedin), its licensed oncology product, has receiv...

Taipei, Taiwan, 02 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has entered into an agreement to acquire Sandoz AG’s Philippines business. Subj...

Taipei, Taiwan, 12 March 2026 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its audited financial results for the full year 2025, delivering the seventh co...

Taipei, Taiwan, 10 March 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for February 2026 of NT$2,238 million, repres...

Taipei, Taiwan, 24 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has filed a New Drug Application (“NDA”) under the 505(b)(2) regulator...

Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B)   Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the com...

Planegg-Martinsried, Germany and Taipei, Taiwan, 11 February 2026 – Formycon AG (FWS: FYB, “Formycon”) and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon&rsqu...

Taipei, Taiwan, 10 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for January 2026 of NT$2,052 million, repr...